Citadel Advisors’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-51,200
| Closed | -$756K | – | 15882 |
|
|
2024
Q1 | $756K | Buy |
51,200
+22,400
| +78% | +$315K | ﹤0.01% | 7504 |
|
|
2023
Q4 | $386K | Sell |
28,800
-49,200
| -63% | -$622K | ﹤0.01% | 8644 |
|
|
2023
Q3 | $962K | Sell |
78,000
-28,400
| -27% | -$344K | ﹤0.01% | 6631 |
|
|
2023
Q2 | $1.31M | Sell |
106,400
-218,900
| -67% | -$2.74M | ﹤0.01% | 5920 |
|
|
2023
Q1 | $4M | Buy |
325,300
+1,200
| +0.4% | +$14.1K | ﹤0.01% | 4164 |
|
|
2022
Q4 | $3.71M | Buy |
324,100
+303,700
| +1,489% | +$2.5M | ﹤0.01% | 4383 |
|
|
2022
Q3 | $77K | Buy |
20,400
+8,500
| +71% | +$39.2K | ﹤0.01% | 11309 |
|
|
2022
Q2 | $71K | Buy |
+11,900
| New | +$67.1K | ﹤0.01% | 11700 |
|
|
2021
Q2 | – | Sell |
-24,200
| Closed | -$152K | – | 15023 |
|
|
2021
Q1 | $152K | Sell |
24,200
-24,800
| -51% | -$177K | ﹤0.01% | 12018 |
|
|
2020
Q4 | $338K | Buy |
49,000
+30,900
| +171% | +$152K | ﹤0.01% | 8866 |
|
|
2020
Q3 | $72K | Buy |
18,100
+6,300
| +53% | +$23.1K | ﹤0.01% | 9455 |
|
|
2020
Q2 | $39K | Sell |
11,800
-1,300
| -10% | -$4.44K | ﹤0.01% | 9401 |
|
|
2020
Q1 | $28K | Buy |
+13,100
| New | +$38.3K | ﹤0.01% | 9220 |
|
|
2018
Q3 | – | Sell |
-24,785
| Closed | -$96K | – | 10117 |
|
|
2018
Q2 | $96K | Buy |
+24,785
| New | +$165K | ﹤0.01% | 8260 |
|
|
2017
Q2 | – | Sell |
-2,936
| Closed | -$71K | – | 8500 |
|
|
2017
Q1 | $71K | Sell |
2,936
-3,012
| -51% | -$75.4K | ﹤0.01% | 6966 |
|
|
2016
Q4 | $191K | Sell |
5,948
-1,081
| -15% | -$46.1K | ﹤0.01% | 6340 |
|
|
2016
Q3 | $351K | Buy |
7,029
+5,656
| +412% | +$235K | ﹤0.01% | 5409 |
|
|
2016
Q2 | $58K | Sell |
1,373
-4,347
| -76% | -$237K | ﹤0.01% | 6377 |
|
|
2016
Q1 | $377K | Buy |
5,720
+4,258
| +291% | +$222K | ﹤0.01% | 4800 |
|
|
2015
Q4 | $91K | Sell |
1,462
-2,059
| -58% | -$145K | ﹤0.01% | 6804 |
|
|
2015
Q3 | $236K | Buy |
3,521
+331
| +10% | +$27K | ﹤0.01% | 5924 |
|
|
2015
Q2 | $310K | Buy |
3,190
+508
| +19% | +$48.3K | ﹤0.01% | 5698 |
|
|
2015
Q1 | $251K | Sell |
2,682
-140
| -5% | -$11.9K | ﹤0.01% | 5900 |
|
|
2014
Q4 | $251K | Sell |
2,822
-724
| -20% | -$52.7K | ﹤0.01% | 5685 |
|
|
2014
Q3 | $245K | Sell |
3,546
-686
| -16% | -$36.7K | ﹤0.01% | 5501 |
|
|
2014
Q2 | $243K | Buy |
4,232
+1,779
| +73% | +$90.3K | ﹤0.01% | 5340 |
|
|
2014
Q1 | $97K | Buy |
2,453
+1,017
| +71% | +$43.5K | ﹤0.01% | 6229 |
|
|
2013
Q4 | $60K | Buy |
1,436
+1,271
| +770% | +$36.8K | ﹤0.01% | 5942 |
|
|
2013
Q3 | $5K | Buy |
+165
| New | +$5.77K | ﹤0.01% | 6589 |
|
Other funds holding MACK
RA
JC
Citadel Advisors's MACK Position: Q2 2024 in Review
Citadel Advisors sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 444 shares — an estimated $6.56K sold.
Citadel Advisors first reported a position in MACK in Q3 2013 and held it in 30 quarters. The position peaked at $5.32M in Q3 2015. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.
- Citadel Advisors reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
- Citadel Advisors sold 444 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $6.56K.
- Citadel Advisors first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2013 and held it in 30 quarters.
- Citadel Advisors's Merrimack Pharmaceuticals, Inc. position peaked at $5.32M in Q3 2015.
- 12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.
Based on Citadel Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.